DPYSL3 and prostate cancer: The fact that dTALE-mediated, locus-specific epigenomic modifications can turn on and off prostate cancer metastasis in vitro and in vivo plainly shows how the CRMP4 CpG methylation status can be an independent biomarker for early clinical prognosis and early laboratory diagnosis of prostate cancer metastasis.